ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

バレニクリン

5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene

HCID 170361
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
249296-44-4
標準SMILES
c1cnc2cc3c(cc2n1)C1CNCC3C1
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
分子式
C13H13N3
平均分子量
211.26 g/mol
単同位体質量
211.11094743

概要

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.

名称と識別子

優先名称
5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
IUPAC
5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
現地名
バレニクリン
英語名
Varenicline
分子式
C13H13N3
分子量
211.26

名称と別名

5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaeneAB01568242_01Varenicline (INN)5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaeneNCGC00247735-01NCGC00247735-02VareniclinVarenicline?SCHEMBL225687CHEMBL556954orb1690005SCHEMBL29363551
名称をさらに表示
バレニクリン7,8,9,10-テトラヒドロ-6α,10α-メタノ-1,4,8-トリアザ-6H-シクロヘプタ[b]ナフタレン(1R,12S)-5,8,14-トリアザテトラシクロ[10.3.1.02,11.04,9]ヘキサデカ-2(11),3,5,7,9-ペンタエンChantixVarenciline10-tetrahydro-Varenicline free base7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2,4(9),5,7,10-pentaeneCS-861Hsdb 7591Cp 526555VARENICLINE
7,8,9,10-tetCP 526555; Champix; ChantixHMS5087H05BDBM50166908s6985T4246LAKOS005145561CS-0396

物性

構造計算による物性補完中

XLogP
0.8
極性表面積
37.8 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
0
重原子数
16
形式電荷
0
複雑度
254

物理化学的性質

融点
138.5 °C · 138.5 °C
沸点
400.6 · 400.6±40.0 °C(Predicted)
比重(密度)
1.247 · 1.247±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Store at -20°C
溶解性
Soluble in DMSO
外見
Powder
酸解離定数(Pka)
9.6 · 9.60±0.20(Predicted)
色
Light yellow to yellow
BCS Class
1 · 1
安定性
Hygroscopic
InChI
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
InChIKey
JQSHBVHOMNKWFT-UHFFFAOYSA-N
SMILES
N1CC2CC(C3=CC4=NC=CN=C4C=C32)C1

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全データ

有毒物質データの
249296-44-4(Hazardous Substances Data)

化学と産業

薬理情報

Protein BindingLess than 20%.
PharmacodynamicsVarenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
Mechanism of Action · 1 件

Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectivity for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.

Biological Half-LifeThe elimination half-life of varenicline is approximately 24 hours
Metabolism/MetabolitesMetabolism is limited (<10%). Most of the active compound is excreted by the kidneys (81%). A minor amount of varenicline is glucuronidated, oxidated, N-formylated, as well as conjugated to form a hexose.
Absorption, Distribution and Excretion · 1 件

Varenicline undergoes minimal metabolism, with 92% excreted unchanged in the urine. Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion possibly via the organic cation transporter, OCT2.

応用分野 · 2 件

説明Varenicline, a partial agonist of the a4b2 nicotinic receptor, is a first-in-class drug launched by Pfizer as an aid to smoking cessation treatment. Varenicline exhibits dual action by decreasing craving and withdrawal symptoms, and by decreasing the reinforcement associated with smoking. The addictive properties of nicotine are thought to be mediated in part through its action as an agonist at α4β2 neuronal nicotinic acetylcholine receptors (nAChRs). Activation of α4β2 receptors by nicotine increases the release of dopamine in the mesolimbic system, an effect that is shared by most drugs of abuse. As nicotine levels decrease, dopamine levels decline, which in turn stimulates the urge to smoke. Additionally, a reduced dopaminergic tone due to abstinence from smoking stimulates craving and the withdrawal syndrome. A partial agonist of α4β2 receptors such as varenicline is expected to elicit a moderate and sustained increase in dopamine levels to relieve craving and withdrawal symptoms. In addition, by competitively binding to a4b2 receptors and inhibiting nicotineinduced dopaminergic activation, a partial agonist could attenuate the pharmacologic reward associated with smoking.

関連反応

12 件
反応記録を作成
HRID 914732 の反応式
HRID 914732生成物として反応物として
HRID 914733 の反応式
HRID 914733反応物として
HRID 1665791 の反応式
HRID 1665791反応物として
HRID 1665792 の反応式
HRID 1665792生成物として
HRID 1665793 の反応式
HRID 1665793生成物として
HRID 1665794 の反応式
HRID 1665794生成物として
HRID 1879292 の反応式
HRID 1879292反応物として
HRID 2092910 の反応式
HRID 2092910反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
249296-44-4
PubChem CID
170361
DTXSID
DTXSID70891447
Nikkaji
J2.566.151F

使用Varenicline is a useful medication for smoking cessation.

上流・下流製品情報

下流製品

酒石酸バレニクリン

補足説明

定義ChEBI: An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.